Sale marks warming of relations
ASTRAZENECA plans to sell its molecule antibiotics business to Pfizer in a deal that will be valued over US$1.5 billion when rights, royalties and other payments are included.
The sale marks a thawing of relations between the UK company and New York-based Pfizer after an acrimonious battle to avoid a takeover just a few years ago.
Under the deal, AstraZeneca will sell the commercialization and development rights in most markets globally outside the United States. It includes an upfront payment of US$550 million.
Luke Miels, the head of the antibiotics business unit at AstraZeneca, says the company is “pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases.”
- About Us
- |
- Terms of Use
- |
-
RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔$粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.